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Abstract 
SWI/SNF chromatin-modification complexes use the energy of ATP hydrolysis to remodel 
nucleosomes and to affect transcription and several cellular processes. Accordingly, their loss 
of function has been associated with malignant transformation. ARID1A (the expression of 
whose product, BAF250a, a key complex component, is lost when mutated) has recently been 
identified as a tumor suppressor gene that is mutated in 46-57% of ovarian clear cell carci-
noma (CCC). The purposes of this study are to assess the frequency of loss of BAF250a 
expression in endometrial CCC and whether this loss has any discernable clinicopathologic 
implications. 34 endometrial carcinomas with a CCC component (including 22 pure CCC, 8 
mixed carcinomas with a 10% CCC component, and 4 carcinosarcomas with a CCC epithelial 
component), were evaluated by immunohistochemistry using a monoclonal antibody directed 
against the human BAF250a protein. 5 (22.7%) of the 22 pure CCC were entirely BAF250a 
negative, whereas the remainder showed diffuse immunoreactivity. None of 4 carcinosar-
comas and only 1 (12.5%) of the 8 mixed carcinomas were BAF250a negative. There was no 
discernable relationship between BAF250a immunoreactivity status and tumor architectural 
patterns (solid, papillary or tubulocystic areas) or cell type (flat, hobnail or polygonal). Of the 
22 patients with pure CCC, 14, 2, 3, and 3 were International Federation of Gynecology and 
Obstetrics stages 1, II, III and IV respectively. Interestingly, all 5 BAF250a negative cases were 
late stage [stages III or IV] as compared with 1 of 17 BAF250a positive cases (p=0.0002). Thus, 
83% (5/6) of all late stage cases were BAF250a [-], as compared with 0 (0%) of the 16 early 
stage (I or II) cases (p=.0002). BAF250a negative and positive cases did not show any statis-
tically significant difference regarding patient age and frequency of lymphovascular invasion or 
myometrial invasion. As may be anticipated from the concentration of late stage cases in the 
BAF250a negative group, patient outcomes were worsened in that group on univariate 
analysis. In conclusion, we found in this pilot assessment that 22.7% of endometrial CCC 
displays complete loss of BAF250a expression. There was a disproportionate concentration 
of BAF250a negative cases in the late stage group, with the attendant possibility of an asso-
ciated worsened prognosis for those CCC patients whose tumors are BAF250a negative. 
These preliminary findings suggest the need for larger analyses to evaluate the prognostic 
significance, if any, of the loss of BAF250a expression in this rare histotype of endometrial 
cancer. 
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INTRODUCTION 
In recent years, there have been significant ad-
vances in deciphering the molecular bases for the 2 
most common histotypes of endometrial carcinoma: 
endometrioid carcinoma and serous carcinoma (1,2). 
The  molecular  underpinnings  of  endometrial  clear 
cell  carcinomas  (CCC),  in  contrast,  remain  largely 
unclear (3). This may be related to its rarity, as CCC 
constitute no more than between 1 and 7% of endo-
metrial  carcinomas  (4,5).  Alternatively,  the  interob-
server  variability  associated  with  its  diagnosis  may 
have historically represented significant impediments 
to segregating a biologically pure dataset (6). In one 
molecular analysis, cases of mixed CCC/ endometrial 
endometrioid  carcinoma  (EEC)  and  mixed 
CCC/endometrial serous carcinomas (ESC) displayed 
such molecular similarities in the CCC and non-CCC 
components that the authors remarked that CCC may 
“represent a heterogeneous group of tumors that arise 
via  different  pathogenetic  pathways”  (7).  Neverthe-
less, the fact that CCC is morphologically distinctive 
(5), displays noteworthy clinical associations such as 
an increased risk of thromboembolic events (8,9), and 
shares gene and protein expression profiles with its 
ovarian counterparts, all indicate that it is indeed a 
distinct  entity.  Additionally,  limited  data  suggests 
that even minor components of CCC may adversely 
impact the prognoses of patients with otherwise pure 
endometrioid carcinomas (10,11). There are no widely 
accepted guidelines for the management of CCC pa-
tients,  and  reported  patient  outcomes  have  histori-
cally been widely variable (12). These findings sug-
gests the need for a more extensive characterization of 
the biologic basis for CCC, not only to identify poten-
tial molecular targets for directed therapies, but also 
to  identify  proteins  whose  expression  patterns  may 
classify  CCC  patients  into  prognostically  relevant 
subgroups.  
The mechanism by  which the large amount  of 
DNA in eukaryotic cells is fitted into the confines of 
the small nucleus in each cell involves a high order 
compaction, which at its most basic subunit, entails 
DNA  being  wrapped  around  a  histone  octamer  to 
form a nucleosome (13-17). Nucleosomes are further 
joined by linker DNA to form highly complex super-
coiled  structures  (heterochromatin),  which  renders 
individual genes relatively inaccessible to the cellular 
transcription  machinery.  Chromatin  remodeling, 
which serves to provide access to these genes by se-
quence-specific transcription factors, may be accom-
plished  by  covalent  modifications  of  the  histones 
(through  acetylation,  phosphorylation  and  methyla-
tion), or the use of ATP-dependent energy to mobilize 
the  nucleosomes  (14-16).  The  SWI/SNF  complex 
(mating type switching/sucrose non-fermenting) be-
longs to the latter class, and is an evolutionarily con-
served multi-unit structure whose subunits may par-
ticipate in transcriptional activation or repression of 
numerous  target  genes  (13-15).  In  addition  to  tran-
scriptional regulation and various aspects of carcino-
genesis  and  progression,  SWI/SNF  complexes  are 
also involved in DNA repair, replication and recom-
bination, mitotic gene regulation, cellular differentia-
tion  and  viral  gene  expression  (13-17).  BAF250a,  a 
subunit of the SWI/SNF complex with ATPase activ-
ity, is encoded by the adenine-thymine (AT)-rich in-
terative  domain  containing  protein  1A  (ARID1A) 
gene,  and  low  frequency  somatic  mutations  of  this 
gene have been identified in a wide spectrum of hu-
man neoplasms (18). Recently Jones et al reported that 
ARID1A mutations are present in 57% of ovarian CCC 
and that the patterns of inactivating mutation were 
suggestive of ARID1A being a tumor suppressor gene 
(19). In a nearly concurrent publication, Wiegand et al 
found that 46% of ovarian CCC, 30% of endometrioid 
carcinomas and 0% of high grade serous carcinomas 
displayed ARID1A mutations (20). Additionally, the 
presence of ARID1A mutations was found to signifi-
cantly correlate with loss of expression of the BAF250a 
protein  as  assessed  by  immunohistochemistry  (20). 
Reports  published  after  these  seminal  papers  have 
subsequently confirmed the ARID1A gene mutation 
and/or loss of expression of the BAF250a protein in a 
significant subset of ovarian CCC (21-26). Since ovar-
ian  and  endometrial  CCC  are  known  to  share  nu-
merous attributes at both the genotypic and pheno-
typic levels (27-29), it can be anticipated that endo-
metrial  CCC  will  similarly  display  loss  of  BAF250a 
expression in a subset. In one study, Guan et al (30) 
reported that 26% of low grade uterine endometrioid 
carcinomas  lack  expression  of  BAF250a;  40%  were 
found to display inactivating ARID1A mutations, and 
none of 12 endometrial serous carcinomas displayed 
these mutations (30). Recently, Wiegand et al reported 
that loss of BAF250a expression is common in high 
grade  endometrial  carcinomas,  including  29-39%  of 
endometrial endometrioid carcinomas, 18% of endo-
metrial  serous  carcinomas,  and  26%  of  endometrial 
CCC (31). However, these analyses did not evaluate 
whether the loss of BAF250a has any clinicopathologic 
correlations. The purposes of the current study are to 
assess the frequency of loss of BAF250a expression in 
endometrial CCC, and whether this loss has any dis-
cernable clinicopathologic implications.  
MATERIALS AND METHODS 
This study was based on an immunohistochem- Journal of Cancer 2012, 3 
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ical  analysis  of  archived  pathologic  material.  Slides 
for 34 endometrial carcinomas with a clear cell com-
ponent were retrieved from the files of the Depart-
ments of Pathology at Vanderbilt University Medical 
Center (Nashville, TN), Brooke Army Medical Center 
(Ft Sam Houston, TX), Stony Brook University Medi-
cal Center (Stony Brook, NY), Wilford Hall Medical 
Center (San Antonio, TX), and Vanguard Pathology 
Associates (Austin, TX). The 34 cases included 22 pure 
CCC (figure 1A), 8 mixed carcinomas with a 10% CCC 
component (Mixed CCC), and 4 carcinosarcomas with 
a  CCC  epithelial  component.  For  the  mixed  CCC 
group, which included 4 mixed ESC/CCC, 1 mixed 
CCC/undifferentiated carcinoma, 2 mixed EEC/CCC, 
and 1 mixed ESC/EEC/CCC, only a slide  with the 
CCC component was evaluated immunohistochemi-
cally in each case. Several of the cases in this study 
have been the subject of immunohistochemical anal-
yses in previous reports from our group (8,32), and 
were  extensively  reviewed  in  the  context  of  those 
studies and the current analysis. Basic clinicopatho-
logic information for each case was documented, in-
cluding patient age, International Federation of Gy-
necology  and  Obstetrics  (FIGO)  stage,  presence  or 
absence of lymphovascular and myometrial invasion, 
adjuvant treatments, and patient outcomes 
Immunohistochemistry  was  performed  on  one 
section  from  each  of  the  study  cases.  Five  mi-
cron-thick  sections  were  placed  on  charged  slides, 
deparaffinized,  and  rehydrated.  All  steps  besides 
dehydration,  clearing,  antigen  retrieval  and  co-
verslipping were performed on the Leica Bond Max 
Immunohistochemical  stainer.  Slides  are  deparaf-
finized.  Heat  induced  antigen  retrieval  was  per-
formed on the Bond Max using their Epitope Retrieval 
2 solution for 30 minutes. Slides were incubated with 
a BAF250a primary antibody for one hour at 1:50 di-
lution.  The  BAF250a  antibody  used  was  a  mouse 
monoclonal  antibody  raised  against  a  recombinant 
protein  corresponding  to  amino  acids  600-1018  of 
human  BAF250a  (PSG3,  sc-32761,  Santa  Cruz  Bio-
technology, Inc., Santa Cruz, CA). The Bond Polymer 
Refine  detection  system  was  used  for  visualization. 
Slides  were  then  dehydrated,  cleared  and  co-
verslipped.  
BAF250a  expression  patterns  were  evaluated 
based on previously described concepts (20). Nuclear 
BAF250a expression is normally present in lympho-
cytes, endothelial cells, and stromal cells. These cells 
accordingly served as internal positive controls, and 
the complete absence of staining in both these positive 
control components and the tumor was used to de-
note one or more technical deficiencies that disquali-
fied the whole assay. For the tumors, staining pattern 
interpretations were performed on the epithelial tu-
mor cells only. Any amount of unequivocal nuclear 
immunoreactivity  was  considered  to  be  BAF250a 
positive (BAF250a[+]). Conversely, a case was classi-
fied as BAF250a negative (BAF250a[-]) if all the epi-
thelial cells displayed no immunoreactivity. BAF250a 
[+]  cases  were  further  classified  as  displaying  mild, 
moderate or extensive immunoreactivity. Mild immu-
noreactivity  was  said  to  be  present  when  less  than 
33% of the tumor on the slide displayed any staining 
or staining was diffusely light irrespective of the dis-
tribution.  Cases  classified  as  displaying  moderate 
immunoreactivity displayed at least moderate inten-
sity of staining in 33%-66% of the tumor on the slide. 
Cases classified as displaying extensive immunoreac-
tivity displayed at least moderate intensity of staining 
in greater than 66% of the tumor on the slide.  
BAF250a [+] and BAF250a[-] negative cases were 
compared  regarding  a  variety  of  clinicopathologic 
variables  using  Fisher’s  Exact  or  Student’s  t  tests  as 
appropriate A 2-tailed p value of less than 0.05 was 
considered  as  statistically  significant  in  all  relevant 
analyses. This study was approved by the institution-
al review board at Vanderbilt University. 
 
RESULTS 
5 (22.7%) of 22 pure CCC were entirely BAF250a 
[-], whereas the remainder showed extensive immu-
noreactivity. The expression patterns appeared to be 
an “all or nothing” phenomenon, in that cases were 
either diffusely positive or entirely negative (figures 
1B-D). There was no discernable relationship between 
predominant tumor architectural patterns (solid, pa-
pillary or tubulocystic areas) or cell type (flat, hobnail 
or  polygonal)  and  BAF250a  immunoreactivity.  In 
BAF250a positive cases, both the stroma and epithelia 
were positive. None of 4 carcinosarcomas and only 1 
(12.5%) of 8 mixed carcinomas were BAF250a nega-
tive. Since the latter did not appear to be broadly dif-
ferent from the pure CCC group regarding frequency 
of BAF250a negativity, these groups were not consid-
ered any further. In the one BAF250a negative mixed 
carcinoma  (a  mixed  ESC/CCC),  both  components 
were negative.  
Clinicopathologic information for the patients in 
the pure CCC group is summarized in table 1. Of the 
22 pts with pure CCC, 14, 2, 3, and 3 were Interna-
tional  Federation  of  Gynecology  and  Obstetrics 
(FIGO) stages 1, II, III and IV respectively. Interest-
ingly,  all  5  BAF250a  negative  cases  were  late  stage 
[FIGO  stage  III  or  IV]  as  compared  with  1  of  17 
BAF250a positive cases (p=0.0002), table 2.  
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Figure  1. A: A representative image of endometrial clear cell 
carcinoma (hematoxylin and eosin, original magnification: 200x). B: 
Complete loss of expression of the BAF250a protein in endo-
metrial clear cell carcinoma. Stromal inflammatory cells (arrow) 
are diffusely immunoreactive (immunoperoxidase, original magni-
fication: 200x). C: Diffuse expression of the BAF250a protein in 
endometrial  clear  cell  carcinoma.  Stromal  inflammatory  cells 
(arrow)  are  also  diffusely  immunoreactive  (immunoperoxidase, 
original  magnification:  200x).  D:  Diffuse  expression  of  the 
BAF250a  protein  in  endometrial  clear  cell  carcinoma. 
Non-neoplastic endometrial epithelial cells (arrow) are also im-
munoreactive (immunoperoxidase, original magnification: 200x) 
 
 
 
Thus,  83%  (5/6)  of  all  late  stage  cases  were 
BAF250a negative, as compared with 0 (0%) of the 16 
early stage (I or II) cases (p=.0002). 1 of 5 BAF250a 
negative cases  showed lymphovascular invasion, as 
compared with 6 of 17 BAF250a positive cases, a sta-
tistically insignificant difference. A similarly insignif-
icant difference between the 2 groups was found re-
garding patient age and the frequency of myometrial 
invasion. As may be anticipated from the concentra-
tion of late stage cases in the BAF250a negative group, 
patient outcomes were worsened, at least on univari-
ate analysis, in that group. Patient outcomes for the 
pure CCC group were as follows: Alive with disease, 
6 patients; No evidence of disease, 11 patients; Dead 
of disease, 4 patients; follow-up unavailable, 1 patient. 
60% of the 5 BAF250a negative patients were dead of 
disease (the other 2 had no evidence of disease), as 
compared with only 1 (6.25%) of 16 BAF250a positive 
patients for whom follow-up information was availa-
ble (p=0.02). 
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Table 1. BAF250a immunoreactivity in cases of pure clear 
cell carcinoma 
Parameters  All cases  BAF250a [-] 
 
BAF250a[+] 
 
Number of cases  22  5  17 
Patient Age 
 mean  70  63  69 
 median  72  69  67 
 Range  54-87  61-78  54-87 
Lymphovascular 
Invasion   Yes  7  1  6 
 No  15  4  11 
Myometrial inva-
sion   Yes  16  5  11 
 No  6  0  6 
Predominant 
Architectural 
pattern 
 
Solid  4  0  4 
Papillary  9  3  6 
Tubulocystic  2  0  2 
Glandular  7  2  5 
FIGO Stage 
 I  14  0  14 
 II  2  0  2 
 III  3  3  0 
 IV  3  2  1 
Late stage (III, IV)  6  5  1 
Follow-up 
Mean (months, 
range) 
47 (11-82)  46 (18-46)  56.5 (11-82) 
Alive with Dis-
ease 
6  0  6 
No evidence of 
dIsease 
11  2  9 
Dead of Disease  4  3  1 
Unavailable  1  0  1 
Adjuvant chemo-
therapy and/or 
radiotherapy   Yes  11  4  12 
No  2  0  2 
Unknown  9  1  8 
 
 
 
Table 2: A comparison of BAF250a[+] and BAF250a[-] 
cases regarding selected clinicopathologic variables. 
Feature  BAF250a [-] 
 
BAF250a[+] 
 
P value* 
Average patient Age  63  69  NS 
Lymphovascular invasion 
present 
1/5  6/17  NS 
Myometrial invasion pre-
sent 
5/5  11/17  NS 
Late stage (stage III or IV)  5/5  1/17  0.0002 
Dead of Disease  3/5  1/16  0.03 
* Fisher’s Exact test (univariate analysis); NS: comparison not sta-
tistically significant 
 
DISCUSSION 
Since SWI/SNF complexes play significant roles 
in  cell-cycle  control,  cellular  differentiation,  DNA 
replication, recombination, and repair, it can be ex-
pected  that  non-functional  or  dysfunctional  com-
plexes  may  contribute  to  malignant  transformation. 
Evidence  of  the  tumor  suppressor  activity  of 
SWI/SNF complexes include the loss of expression of 
complex subunits in some cancer cell lines, genetic or 
epigenetic  alterations  of  associated  genes  in  some 
cancers,  the  promotion  of  tumorigenesis  in  animal 
knock-out  models,  and  the  direct  involvement  of 
SWI/SNF complexes in the regulation of numerous 
cancer-related target pathways (13-16). SNF, a highly 
conserved core subunit of the SWI/SNF complex, is 
inactivated  through  biallelic  deletions  or  truncating 
mutations in most cases of malignant rhabdoid tumor, 
a highly aggressive pediatric malignancy (14-16). SNF 
mutations have also been described in medulloblas-
tomas, choroid plexus carcinomas, central  primitive 
neuroectodermal  tumors,  hepatoblastomas,  epitheli-
oid  sarcomas,  poorly  differentiated  chordomas, 
meningiomas, familial schwannomatosis, undifferen-
tiated sarcomas, extraskeletal myxoid chondrosarco-
mas,  and  the  blast  crisis  phase  of  chronic  myeloid 
leukemia  (15,16).  PBRM1,  the  gene  that  encodes 
BAF180, another SWI/SNF complex subunit, is the 2nd 
most frequently mutated gene (41%) in renal cell car-
cinomas (33), and inactivating PBRM1 mutations have 
been identified in both renal cell and breast carcinoma 
cell lines (33,34) . As previously noted, ARID1A mu-
tations have been identified in a wide variety of tu-
mors (18-20). Inactivating mutations in the gene that 
encodes BRG1, another SWI/SNF subunit have been 
identified  in  lung  carcinoma,  medulloblastoma  and 
malignant rhabdoid tumors as well as cancer cell lines 
from a variety of tumor types (15). There is evidence 
that  SWI/SNF  complexes  participate  in  and  is  in-
volved in regulating several cancer-related pathways 
(including  the  retinoblastoma  and  Hedgehog  path-
ways, interferon-beta and nuclear-hormone receptor 
signaling,  among  others),  through  their  interaction 
with important proto-oncogenes and tumor suppres-
sor genes (13,15). Finally, there is some evidence that 
SWI/SNF complexes are involved in the promotion of 
tumor metastases through their interactions with cel-
lular  cytoskeletal  structure  in  a  manner  that  affects 
motility, as well as their interactions with the poten-
tially  metastasis-associated  glycoprotein,  CD44  (15). 
The  myriad  ways  in  which  alterations  of  the 
SWI/SNF  complexes  are  involved  in  human  neo-
plasia, are reviewed in detail elsewhere (13-17).  Journal of Cancer 2012, 3 
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The concept that the mutational and/or expres-
sion status of some SWI/SNF subunits and associated 
genes may have prognostic significance, is a natural 
avenue for investigative efforts, given the aforemen-
tioned roles of SWI/SNF as putative tumor suppres-
sors.  This  possibility  presents  the  opportunity  for 
better prognostication by  segregating those patients 
that  may  require  unconventional  or  even  more  ag-
gressive therapeutic intervention. Additionally, given 
the  reversible  nature  of  the  epigenetic  silencing  of 
some  SWI/SNF-associated  genes  in  some  tumors 
(subunit BRM, for example [35]), the maximal efficacy 
of  molecularly-targeted  therapies  may  be  best 
achieved in specific patient subsets. Loss of expres-
sion of BRM and/or BRG1, both of which are subunits 
of the SWI/SNF complex, has already been reported 
to be associated with poor prognosis in patients with 
lung carcinomas independent of stage (36,37). In one 
study of head and neck cancers, frequent chromoso-
mal deletion at 9p24, the locus for the BRM gene, was 
detected and was associated with worsened prognosis 
(38).  Loss  of  SNF5  has  been  associated  with  poor 
prognosis in patients with malignant melanoma (39), 
and aberrant expression of the BRM and BRG1 genes 
has been associated with prostate cancer development 
and progression (40).  
Published data on the clinicopathologic signifi-
cance  of  BAF250a  loss  of  expression  is  somewhat 
conflicting,  at  least  as  they  relate  to  ovarian  CCCs 
(21,23,24,26). Three studies found no correlation be-
tween loss of BAF250 a expression and a variety of 
clinicopathologic variables, including the patient age, 
stage, survival, tumor size and laterality, presence of 
residual  tumor  after  initial  surgery,  response  to 
chemotherapy,  nodal  metastases,  and  histological 
patterns, each of which were evaluated in at least 1 
study ( 21,23,26). However, in a recent study, Katagiri 
et al (24) found loss  of BAF250a to be a significant 
negative prognostic factor. The authors evaluated 60 
ovarian  CCC  for  BAF250  expression  by  immuno-
histochemistry  (24).  On  univariate  analysis,  loss  of 
BAF250a was significantly correlated with advanced 
stage, high CA125 levels, shorter progression-free and 
overall  survival  in  patients  with  platinum-based 
chemotherapeutic regimens, chemoresistance and not 
patient  age  or  status  of  residual  tumor  (24).  Addi-
tionally, only loss of BAF250a expression was a pre-
dictor  of  progression  free  survival  on  multivariate 
analysis (24). 
In the current study, we evaluated the frequency 
of loss  of BAF250a expression in endometrial CCC, 
and assessed whether loss of expression of this pro-
tein  has  any  clinical  or  pathologic  significance.  We 
found 22.7% of pure endometrial CCC to be entirely 
BAF250a negative, a figure that is largely similar to 
the 26% reported by Wiegand et al in the only other 
analysis  of  the  subject  (31).  Regarding  a  potential 
correlation with clinicopathologic variables, we found 
no  significant  association  between  BAF250a  expres-
sion and patient age, frequency of lymphovascular or 
myometrial  invasion,  and  histologic  architectural 
patterns.  However,  we  identified  a  statistically  sig-
nificant association with FIGO stage, as patients with 
BAF250a  negative  tumors  were  significantly  more 
likely  to  be  advanced  stage  on  univariate  analysis. 
This  apparent  concentration  of  BAF250a  negative 
cases in the late stages was reflected in the patients’ 
worsened  outcomes.  However,  larger  analyses  that 
would  allow  for  multivariate  stratification  are  re-
quired to definitively answer this question.  
In summary, we report here for the first time that 
loss of BAF250a expression, which was seen in 22.7% 
of endometrial CCC, may have clinicopathologic sig-
nificance. The current study is a pilot assessment that 
is  limited  by  the  small  data  size.  However,  some 
noteworthy  and  intriguing  trends  were  discernable, 
including  the  disproportionate  concentration  of 
BAF250a negative cases in the late stage group and 
the  attendant  possibility  of  an  associated  worsened 
prognosis.  These  preliminary  findings  suggest  the 
need  for  larger  analyses  to  evaluate  the  prognostic 
significance, if any, of the loss of BAF250a expression 
in this rare histotype of endometrial cancer. The fact 
that BAF250a expression is lost in only a small per-
centage  of  endometrial  CCC  may  suggest  that 
ARID1A mutations plays a significant role in only a 
small  proportion  of  CCC,  or  that  these  mutations 
represent only a small component of the genesis of 
this specific tumor type. It may also bolster the argu-
ment that endometrial CCC represents a phenotype 
that arises via a multitude of different pathways (3,7), 
with no one pathway being notably dominant. How-
ever, it is unclear if those clear cell carcinomas whose 
pathogenesis does involve ARID1A mutations, repre-
sents a clinicopathologically distinct group with de-
finable characteristics. 
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